SOLVD


Also found in: Acronyms.

SOLVD

Cardiology A series of clinical trials–Studies of Left Ventricular Dysfunction that evaluated the effect of antihypertensives–eg, with enalapril, an ACE inhibitor, on M&M in Pts with CHF. See ACE inhibitor, Congestive heart failure Consensus II, Enalapril.
References in periodicals archive ?
8% of the original SOLVD participants were tracked down 12 years after the studies had formally ended to learn how the patients had subsequently fared.
At the conclusion of the SOLVD prevention trial, patients with asymptomatic left ventricular dysfunction who received enalapril had significantly lower rates of MI and hospitalization than those who received placebo.
At the end of the SOLVD treatment trial, patients with CHE in the enalapril arm had a significant survival advantage: 64%, vs.
Even so, XSOLVD probably underestimates the true benefits of lifelong ACE inhibitor therapy That's because for much of the 12-year follow-up, most participants in the original control group were actually on an ACE inhibitor, which in the aftermath of the SOLVD trials had become the standard of care, observed Dr.
Only about half of the late survival benefit documented in the 12 years after conclusion of the SOLVD prevention trial appeared to be due to a reduction in rates of acute MI and CHF during the course of the study; the other half involved other mechanisms, perhaps including left ventricular and vascular remodeling, Dr.
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejections fractions: SOLVD Investigators.
Selected trials of angiotensin-converting enzyme inhibitors in heart failure Treatment group Trial (year) N NYHA class mortality CONSENSUS I (29) (1987) 253 IV 26% V-HeFT II (30) (1991) 804 I-III 18% SOLVD treatment (31) (1991) 2569 II/III 35% SOLVD (32) prevention (1992) 4228 I 15% SAVE (33) (1992) 2231 Post-MI (EF <40%) 20% Control group Hazard Trial (year) mortality ratio P value CONSENSUS I (29) (1987) 44% 0.
In the 3-year SOLVD (Studies of Left Ventricular Dysfunction) trial, more than 6,700 American, Canadian, and Belgian patients took enalapril or placebo; they were followed for an additional 9 years to assess life expectancy.
Results of NIH's SOLVD study Treatment Trial (Studies of Left Ventricular Dysfunction), which supported the broadened indication, demonstrated:
The SOLVD Treatment Trial, a placebo-controlled trial reported in the August 1, 1991, issue of The New England Journal of Medicine, followed 2,569 patients with all degrees of symptomatic heart failure for up to 55 months.